UK regulator advises US not to rush into third party review
This article was originally published in Clinica
US medical device manufacturers regard the European Directives as the best of all possible systems, to which the US must aspire - quickly. It is not and don't, Alan Kent, chief executive of the UK Medical Devices Agency, advised a Food and Drug Law seminar in Washington, DC, last month.
You may also be interested in...
P&G’s oral care business drove 35% of total category market growth in the firm’s fiscal 2020 and exemplifies its growth strategy for all segments – grow entire categories rather than take competitors’ market share, says CFO Jon Moeller.
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.
The US Food and Drug Administration posted two device-related closeout letters in November.